Waters opens solution centre in Singapore

Monday, 04 March, 2013

Waters Corporation, an analytical science solutions developer and provider headquartered in Massachusetts, has announced the opening of a new solution centre in Singapore. Housed in Singapore Science Park II, Waters Solution Centre is equipped with analytical application development and demonstration capabilities and training facilities dedicated to addressing the needs of laboratory scientists throughout South East Asia.

“The scientific challenges our customers face in South East Asia are unique to this part of the world and Waters’ new solution centre is designed to address these challenges to ensure our customers are successful,” said Mike Harrington, Vice President Europe and Asia Pacific for the Waters Division.

“Comprising a team of skilled analytical scientists, many at post-doctoral levels, who will offer technical advice and/or develop applications to solve analytical issues, the solution centre will serve the increasing important markets of South East Asia along with Singapore and Australia.”

Waters Solution Centre in Singapore further strengthens the footprint the global company already has in the region. In addition to establishing Waters R&D facility for Engineering in Singapore, the Waters Solution Centre is an extension of Waters’ commitment to promote R&D in Singapore in support of the development of Singapore’s biomedical sciences sector.

“The opening of Waters Solution Centre marks another milestone in our commitment to Singapore,” said Mathieu Laouenan, General Manager, South East Asia & Pacific Operations, Waters Corporation.

“Singapore is a key strategic location for us in Asia and in particular South East Asia at two levels - business and talents. Not only does it bring us closer to our customers in this region, Singapore as a research hub is also where international and local research talents and minds gather.”

The solution centre will offer users the Waters Omics Research Platform Solutions for use in the pharmaceutical and life sciences, food and clinical research areas. With the world’s growing emphasis on medical care, these solutions will help the medical community in South East Asia realise the promise of personalised medicine with a ‘bench to bedside’ approach to optimising the drug discovery process.

“Through development of applications to address the challenges faced by scientists in this part of the world, Waters hopes to leverage its momentum in food safety analysis and life sciences innovation and expand its capability in traditional medicine research and the development of new tools for the chemical industry,” said Mark Ritchie, Senior Manager of Waters Solution Centre.

The centre will also be equipped with Waters’ separation science and mass spectrometry technology, the Acquity Ultra Performance Convergence Chromatography (UPC2). Acquity UPC2 is a complementary chromatography platform said to have workflow, application and environmental impact benefits over liquid and gas chromatography platforms. This technology replaces the use of organic solvents with safe, green CO2 while increasing analytical performance.

Users from all market segments throughout South East Asia are encouraged to contact the solution centre to better understand the features and benefits of Waters Omics Research Platform Solutions, Acquity UPC2 or any of Waters’ separation science and mass spectrometry technologies.

Related News

Cicada Innovations opens HealthTech Hub in Western Sydney

The incubation facility is situated within one of Australia's largest health and biomedical...

New Melbourne-based facility to deliver human challenge trials

Doherty Clinical Trials was established to accelerate the development of novel medicines and...

QUT's lunar testbed nears completion

A lunar testbed, understood to be the first of its kind in Australia, is currently under...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd